Compare AMWL & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMWL | ONCY |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.2M | 107.3M |
| IPO Year | 2020 | 2002 |
| Metric | AMWL | ONCY |
|---|---|---|
| Price | $10.98 | $0.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $7.40 | $7.33 |
| AVG Volume (30 Days) | 151.3K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | $2,505.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $0.77 |
| 52 Week High | $13.45 | $1.51 |
| Indicator | AMWL | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 41.89 |
| Support Level | $4.49 | $0.81 |
| Resistance Level | N/A | $1.06 |
| Average True Range (ATR) | 0.92 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 48.54 | 8.41 |
American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.